



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/724,570

11/28/2000

Dale B. Schenk

209-US-NEW6

6101

7590

04/10/2003

Nina M Ashton
Elan Pharmaceuticals Inc
800 Gateway Boulevard
South San Francisco, CA 94080

EXAMINER

NICHOLS, CHRISTOPHER J

ART UNIT

PAPER NUMBER

1647

DATE MAILED: 04/10/2003

2

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.		Applicant(s)	
	09/724,570		SCHENK, DALE B.	
	Examiner		Art Unit	
	Christopher Nichols, Ph.D.		1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 November 2000.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-57 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-57 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: |

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-10, drawn to a pharmaceutical composition comprising an **agent** effective to induce an immune response against an amyloid component, classified in class 514, subclass 2, for example.
 - II. Claims 11-25, drawn to a method of preventing or treating a disorder characterized by amyloid deposition by administering an agent effective to induce an immune response against an amyloid component classified in class 514, subclass 12, for example.
 - III. Claims 26-28 drawn to a method of determining the prognosis of a patient by measuring immunoreactivity of the patient's serum against amyloid component, classified in class 424, subclass 9.2, for example.
 - IV. Claims 29-39 and 42-43, drawn to a method of preventing or treating a disorder characterized by amyloid deposition by administering an **antibody** that specifically binds to an amyloid component, classified in class 424, subclass 130.1, for example.
 - V. Claims 40-41, drawn to a method of preventing or treating a disorder characterized by amyloid deposition by administering a **nucleic acid** encoding an antibody that specifically binds to an amyloid component, classified in class 514, subclass 44, for example.
-

Art Unit: 1647

VI. Claims 44-57, drawn a pharmaceutical composition comprising an antibody that specifically binds to an amyloid component, classified in class 424, subclass 130.1, for example

2. The inventions are distinct, each from the other because of the following reasons:

3. Inventions I and VI are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function and each has an independent utility, that is distinct for each invention which cannot be exchanged. The pharmaceutical compositions of Group I and VI are defined by different chemical and physical characteristics.

4. Inventions I and II are related as product and process of use. However, the inventions are distinct because the agent of Group I as claimed can be used in materially different methods, such as in a method of raising antibodies, also the method of Group II can be practiced without the agent of Group I, such as by using antibodies against an amyloid competent.

5. Inventions VI and IV are related as product and process of use. However, the inventions are distinct because the antibody of Group IV as claimed can be used in materially different methods, such as it can be used diagnostically, also the method of Group IV can be practiced without the antibody of Group VI, such as by using an agent that induces an immune response against an amyloid component.

6. Inventions II-V are independent and distinct, each from the other, because the methods are practiced with materially different process steps for materially different purposes and each

~~method requires a non-coextensive search because of different goals. The methods are distinct~~

because each assay is performed for divergent purposes. The methods of inventions II, IV and V

Art Unit: 1647

are methods of treating a disorder by using different pharmaceutical compositions, while the method of invention III determines the prognosis of a patient.

7. Inventions I and III-V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the methods of Groups III-IV neither use nor produce the agent of group I.

8. Inventions VI and II-III, V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the methods of Groups II-III, and IV neither use nor produce the antibody of group VI.

9. This application contains claims directed to the following patentably distinct species of the claimed invention:

- a. Serum Amyloid A protein (ApoSSA)
- b. Immunoglobulin light chain
- c. Immunoglobulin heavy chain
- d. ApoAI
- e. Transthyretin
- f. Lysozyme
- g. Fibrogen α chain
- h. Gelsolin
- i. Cystatin C
- j. Amyloid β protein precursor (β -APP)

Art Unit: 1647

- k. Beta₂ microglobulin
- l. Prion precursor protein (PrP)
- m. Atrial natriuretic factor
- n. Keratin
- o. Islet amyloid polypeptide
- p. A peptide hormone
- q. Synuclein
- r. Mutant proteins
- s. Protein fragments
- t. Proteolytic peptides

10. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 3, 13, 34, and 49 generic.

11. If applicant selects any one of Inventions I, II, IV, or VI, one species from the amyloid component group must be chosen to be fully responsive.

12. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

13. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the

~~limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after~~

Art Unit: 1647

the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

14. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

15. This application contains claims directed to the following patentably distinct species of the claimed invention:

- u. AA
 - v. AL
 - w. ATTR
 - x. AApoA1
 - y. Alys
 - z. Agel
 - aa. Acys
 - bb. Ab
 - cc. AB₂M
 - dd. AScr
 - ee. Acal
 - ff. AIAPP
 - gg. Synuclein-NAC fragment
-

Art Unit: 1647

16. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 5, 6, 15, 16, 35, and 50 generic.

17. If applicant selects any one of Inventions I, II, IV, or VI, one species from the amyloid component fragment group must be chosen to be fully responsive.

18. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

19. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

20. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

21. Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized

~~divergent subject matter as defined by MPEP § 808.02, the Examiner has prima facie shown a~~

Art Unit: 1647

serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

22. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

23. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.

24. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1647


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Christopher James Nichols, Ph.D.** whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Gary Kunz, Ph.D.** can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN
April 7, 2003


GARY KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600